Skip to content

The HCV Treatment Pipeline

  • Chad Cipiti

July 2018 Annette Gaudino HCV TREATMENT PIPELINE: THE DEFERRED DREAM OF TREATMENT FOR ALL Generic combinations of direct-acting antivirals (DAAs), including sofosbuvir/daclatasvir show bioequivalence compared to originators with equivalent sustained virological responses (SVR). Both sofosbuvir/daclatasvir and sofosbuvir/ravidasvir demonstrate SVR rates…

Read more

White House and Congress Must Boldly Address Drug Pricing and Ensure Access to Critical HIV, HCV, and TB Medications

  • Chad Cipiti

Treatment Action Group (TAG), NASTAD (National Alliance of State & Territorial AIDS Directors) and HIVMA (HIV Medicine Association join together in submitting collaborative comments today in response to the Department of Health and Human Services (HHS) public request for information (RFI) on the agency’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.

Read more

TAGline Spring 2018

  • Chad Cipiti

Bend the Curves: Incremental change—activism that successfully defends or advances critical research or policy—can sometimes feel inconsequential, particularly when it is hard won, resource intensive, and intangible.

Read more

Updated Training Manual for Treatment Advocates: Hepatitis C Virus & Coinfection with HIV

  • Chad Cipiti

The purpose of this Training Manual is to provide information for you and your community. This information can be used to advocate for access to prevention and diagnosis of, and care and treatment for, hepatitis C virus (HCV). The manual is written by and for people who are not medical specialists. We’re treatment activists who learned about HCV because it was a problem for people in our communities.

Read more
Back To Top